Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
10.42
+0.16 (1.56%)
Jan 21, 2025, 4:00 PM EST - Market closed
Cullinan Therapeutics Employees
Cullinan Therapeutics had 85 employees as of December 31, 2023. The number of employees increased by 23 or 37.10% compared to the previous year.
Employees
85
Change (1Y)
23
Growth (1Y)
37.10%
Revenue / Employee
n/a
Profits / Employee
-$1,688,694
Market Cap
606.73M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 85 | 23 | 37.10% |
Dec 31, 2022 | 62 | 31 | 100.00% |
Dec 31, 2021 | 31 | 7 | 29.17% |
Dec 31, 2020 | 24 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
CGEM News
- 11 days ago - Cullinan Therapeutics' CLN-978 And Zipalertinib Look Promising In NSCLC - Seeking Alpha
- 13 days ago - Cullinan Therapeutics: Casting A Wide Net With Their Pipeline - Seeking Alpha
- 2 months ago - Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 - GlobeNewsWire
- 2 months ago - Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference - GlobeNewsWire
- 2 months ago - Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024 - GlobeNewsWire
- 3 months ago - Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus - GlobeNewsWire
- 4 months ago - Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus - GlobeNewsWire
- 4 months ago - Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024 - GlobeNewsWire